Key result
PCSK9 inhibitors reduce MACE ~12% vs. control in patients with ACS.
Why the study?
PCSK9 inhibitors may reduce major adverse cardiovascular events in patients with acute coronary syndrome, warranting a compilation of evidence to evaluate their lipid-lowering and event-prevention efficacy.
Do PCSK9 inhibitors reduce major adverse cardiovascular events and improve lipid profiles in patients with acute coronary syndrome?
Meta-Analysis (n=19,649)
Double-blind
Randomized
Yes
Do PCSK9 inhibitors reduce major adverse cardiovascular events and improve lipid profiles in patients with acute coronary syndrome?
PCSK9 inhibitors effectively lower atherogenic lipoproteins and reduce the risk of major adverse cardiovascular events in patients with acute coronary syndrome without notable safety concerns.
Answers are grounded in this paper and cite their sources.
Supports PCSK9 inhibitor use in ACS to reduce MACE; extends stable CAD evidence to acute settings.
Background: PCSK9 MaB (Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor) may reduce the occurrence of major adverse cardiovascular events (MACEs) in patients diagnosed with acute coronary syndrome (ACS). In this meta-analysis, we conducted a thorough compilation of evidence from established clinical studies to evaluate PCSK9 MaB's capacity to control blood lipid levels and prevent MACEs in ACS patients. Methods: We conducted searches on Pubmed, Embase, the Cochrane Library, and Web of Science to identify relevant articles. Data from ACS patients were extracted using a standardized format for aggregating data. We calculated the risk ratio (RR) for MACE and assessed changes in blood lipid parameters. All statistical analyses were performed using RevMan. Results: 0.01). Importantly, there were no significant differences in adverse reactions between the PCSK9 MaB group and the control group. Conclusions: PCSK9 MaB, whether used as a standalone treatment or in combination with other therapies, can effectively inhibit PCSK9. It substantially lowers key blood lipid parameters, including low-density lipoprotein (LDL), ApoB, and triglycerides, all without giving rise to notable safety concerns.
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2024) conducted a meta-analysis in Acute Coronary Syndrome (n=19,649). PCSK9 Inhibitors (Alirocumab, Evolocumab) vs. Placebo or Standard of care was evaluated on Major adverse cardiovascular events (MACE) (RR 0.88, 95% CI 0.81, 0.97, p=<0.01). PCSK9 inhibitors significantly reduced the risk of major adverse cardiovascular events (RR 0.88) compared to placebo or standard care in patients with acute coronary syndrome.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: